3 min read FDA Moves to End Compounded Semaglutide and Tirzepatide What It Means for Weight Loss Patients The FDA Just Proposed a Major Change to Compounded Weight Loss Drugs If you've been following the news about weight loss medications, you may have heard that the FDA announced a significant regulatory change on April 30, 2026
Have Your Say These messages and the hundreds more like them help MOAA put a face on what some policymakers may see as a purely financial issue
Under the gesetzliche Krankenversicherung (GKV) public insurance system, GLP-1 medicines including Ozempic are covered when prescribed for type 2 diabetes
Endocrinology (2011) 152(3):82835.10.1210/en.2010-0757 145 RaoAUShaoNAslanianRGChanTYDegradoSJWangLet alDiscovery of a potent thiadiazole class of histamine H3 receptor antagonist for the treatment of diabetes
Semaglutide (Ozempic for diabetes, Wegovy for weight management) and tirzepatide (Mounjaro, licensed for type 2 diabetes in the UK)a dual GLP-1/GIP receptor agonistare highly effective but are associated with gastrointestinal side effects that are dose-dependent
Convenience, cost, and lifestyle Convenience: Oral drops appeal to people who strongly prefer needle-free options